FY2026 EPS Forecast for PTC Therapeutics Lowered by Analyst

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Cantor Fitzgerald lowered their FY2026 EPS estimates for PTC Therapeutics in a research note issued on Wednesday, August 20th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of ($6.71) for the year, down from their previous estimate of ($6.57). Cantor Fitzgerald currently has a “Overweight” rating and a $120.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

Several other equities research analysts have also recently weighed in on the stock. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research note on Friday, August 8th. Bank of America cut their price target on shares of PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating for the company in a research note on Wednesday. Truist Financial raised their price target on shares of PTC Therapeutics from $80.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Robert W. Baird set a $70.00 price target on shares of PTC Therapeutics in a research note on Friday, August 8th. Finally, Citigroup raised their price target on shares of PTC Therapeutics from $40.00 to $50.00 and gave the stock a “neutral” rating in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.15.

PTC Therapeutics Stock Performance

NASDAQ PTCT opened at $50.57 on Friday. The firm has a 50-day simple moving average of $48.86 and a 200 day simple moving average of $49.03. PTC Therapeutics has a twelve month low of $30.41 and a twelve month high of $58.38. The stock has a market cap of $4.02 billion, a PE ratio of 7.26 and a beta of 0.54.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.24. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $178.88 million during the quarter, compared to analysts’ expectations of $173.01 million. During the same quarter last year, the company earned ($1.29) earnings per share. The firm’s revenue was down 4.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC raised its stake in shares of PTC Therapeutics by 424.4% in the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 522 shares during the last quarter. Quantbot Technologies LP increased its holdings in shares of PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 551 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 320 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 441 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 814 shares in the last quarter.

Insider Buying and Selling

In other news, CEO Matthew B. Klein sold 10,739 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $51.74, for a total value of $555,635.86. Following the completion of the transaction, the chief executive officer owned 337,767 shares in the company, valued at approximately $17,476,064.58. The trade was a 3.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Pierre Gravier sold 2,516 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total transaction of $124,441.36. Following the completion of the transaction, the chief financial officer owned 71,920 shares of the company’s stock, valued at $3,557,163.20. This trade represents a 3.38% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.